Horizon Discovery plcの時価総額
Horizon Discovery plcの時価総額は何ですか。
Horizon Discovery Group plcの時価総額は391.19M$です。
時価総額の定義は何ですか。
時価総額は、取引された会社の発行済株式の市場価値であり、一定期間のb株式に発行済株式数を掛けたものに等しい。
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
LSEのセクタHealth Careにおける時価総額の企業と比べるHorizon Discovery plc
Horizon Discovery plcは何をしますか。
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Horizon Discovery plcと類似の時価総額
- Temple & Websterの時価総額は390.76M$です。
- Sangoma Technologiesの時価総額は390.78M$です。
- Seerの時価総額は390.88M$です。
- Whitefieldの時価総額は390.94M$です。
- Flaherty & Crumrine Dynamic Preferred and Income Fund Incの時価総額は391.12M$です。
- Farmers & Merchants Bancorpの時価総額は391.19M$です。
- Horizon Discovery plcの時価総額は391.19M$です。
- FBD plcの時価総額は391.27M$です。
- Apollo Endosurgery Incの時価総額は391.37M$です。
- Greentech Technology Internationalの時価総額は391.53M$です。
- Geronの時価総額は391.63M$です。
- Ramaco Resources Incの時価総額は391.69M$です。
- Fineotex Chemicalの時価総額は391.79M$です。